Telix Pharmaceuticals Limited Stock Buy Hold or Sell Recommendation
| TLPPF Stock | USD 16.00 0.82 5.40% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Telix Pharmaceuticals Limited is 'Strong Sell'. Macroaxis provides Telix Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TLPPF positions.
Check out Telix Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Telix and provide practical buy, sell, or hold advice based on investors' constraints. Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Telix |
Execute Telix Pharmaceuticals Buy or Sell Advice
The Telix recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Telix Pharmaceuticals Limited. Macroaxis does not own or have any residual interests in Telix Pharmaceuticals Limited or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Telix Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Telix Pharmaceuticals Trading Alerts and Improvement Suggestions
| Telix Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Telix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.9 M. Net Loss for the year was (80.51 M) with profit before overhead, payroll, taxes, and interest of 5.05 M. | |
| Telix Pharmaceuticals Limited has accumulated about 122.61 M in cash with (59.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders |
Telix Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Telix analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Telix analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Telix Pharmaceuticals Returns Distribution Density
The distribution of Telix Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Telix Pharmaceuticals' future price movements. The chart of the probability distribution of Telix Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Telix Pharmaceuticals Limited price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Telix Pharmaceuticals returns is essential to provide solid investment advice for Telix Pharmaceuticals.
| Mean Return | 0.32 | Value At Risk | -5.03 | Potential Upside | 5.55 | Standard Deviation | 3.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Telix Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Telix Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Telix Pharmaceuticals or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Telix Pharmaceuticals' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Telix pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.32 | |
β | Beta against Dow Jones | -0.15 | |
σ | Overall volatility | 3.27 | |
Ir | Information ratio | 0.06 |
Telix Pharmaceuticals Volatility Alert
Telix Pharmaceuticals Limited shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Telix Pharmaceuticals' pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Telix Pharmaceuticals' pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Telix Pharmaceuticals Fundamentals Vs Peers
Comparing Telix Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Telix Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Telix Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Telix Pharmaceuticals or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Telix Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Telix Pharmaceuticals to competition |
| Fundamentals | Telix Pharmaceuticals | Peer Average |
| Return On Equity | -1.55 | -0.31 |
| Return On Asset | -0.41 | -0.14 |
| Operating Margin | (3.95) % | (5.51) % |
| Current Valuation | 1.39 B | 16.62 B |
| Shares Outstanding | 317.02 M | 571.82 M |
| Shares Owned By Insiders | 27.60 % | 10.09 % |
| Shares Owned By Institutions | 13.59 % | 39.21 % |
| Price To Book | 21.16 X | 9.51 X |
| Price To Sales | 52.21 X | 11.42 X |
| Revenue | 4.9 M | 9.43 B |
| Gross Profit | 5.05 M | 27.38 B |
| EBITDA | (70.07 M) | 3.9 B |
| Net Income | (80.51 M) | 570.98 M |
| Cash And Equivalents | 122.61 M | 2.7 B |
| Cash Per Share | 0.39 X | 5.01 X |
| Total Debt | 2.57 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 3.21 X | 2.16 X |
| Book Value Per Share | 0.34 X | 1.93 K |
| Cash Flow From Operations | (59.33 M) | 971.22 M |
| Earnings Per Share | (0.20) X | 3.12 X |
| Number Of Employees | 11 | 18.84 K |
| Beta | 2.31 | -0.15 |
| Market Capitalization | 1.44 B | 19.03 B |
| Total Asset | 109.81 M | 29.47 B |
| Net Asset | 109.81 M |
Telix Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Telix . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 16.0 | |||
| Day Typical Price | 16.0 | |||
| Price Action Indicator | 0.41 | |||
| Period Momentum Indicator | 0.82 | |||
| Relative Strength Index | 40.88 |
About Telix Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Telix Pharmaceuticals Limited? Buying financial instruments such as Telix Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Telix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Currency Funds Thematic Idea Now
Currency Funds
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out Telix Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.